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Abstract
Introduction: Although pathogenesis of small vessel disease is poorly understood, increasing evidence suggests that
endothelial dysfunction may have a relevant role in development and progression of small vessel disease. In this cross-
sectional study, we investigated the associations between imaging signs of small vessel disease and blood biomarkers of
endothelial dysfunction at two different time points in a population of ischaemic stroke patients.
Patients and methods: In stroke patients treated with intravenous thrombolysis, we analysed blood levels of von
Willebrand factor, intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and vascular endothelial growth
factor. Three reviewers independently assessed small vessel disease features using computed tomography. At baseline
and 90 days after the index stroke, we tested the associations between single and combined small vessel disease features
and levels of blood biomarkers using linear regression analysis adjusting for age, sex, hypertension, diabetes, smoke.
Results: A total of 263 patients were available for the analysis. Mean age (SD) was 69 (13) years, 154 (59%) patients were
male.We did not find any relation between small vessel disease and endothelial dysfunction at baseline. At 90 days, leukoaraiosis
was independently associated with intercellular adhesionmolecule-1 (b¼ 0.21; p¼ 0.016) and vascular cell adhesionmolecule-
1 (b¼ 0.22; p¼ 0.009), and lacunes were associated with vascular endothelial growth factor levels (b¼ 0.21; p¼ 0.009)
whereas global small vessel disease burden was associated with vascular endothelial growth factor (b¼ 0.26; p¼ 0.006).
Discussion: Leukoaraiosis and lacunes were associated with endothelial dysfunction, which could play a key role in
pathogenesis of small vessel disease.
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Conclusions: Small vessel disease features and total burden were associated with endothelial dysfunction 90 days after
the stroke, whereas there was no relation during the acute phase. Our results suggest that endothelial dysfunction,
particularly vascular endothelial growth factor, is involved in pathological process of small vessel disease.
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Introduction
The term small vessel disease (SVD) describes a hetero-
geneous condition with different underlying aetiologies
affecting microcirculation in the brain.1 SVD represents
a frequent cause of vascular dementia, causes around
one-fifth of the strokes in the world and is recognised
as a disease with a high social impact.2,3 Magnetic res-
onance (MR) is the gold standard to investigate in vivo
SVD, although considerable information can also be
gathered with computed tomography (CT). CT signs
of SVD are lacunar infarct, leukoaraiosis (i.e. white
matter changes) and cerebral atrophy.
Pathogenesis of SVD is poorly understood; howev-
er, several studies suggested a key role of endothelial
dysfunction in development and progression of SVD.4
Endothelial dysfunction has been associated with lacu-
nar infarcts5 and with increased cerebral white matter
hyperintensity.6 Although several biomarkers of endo-
thelial dysfunction have been investigated in relation
with SVD, studies reported conflicting results,7 and
no marker of endothelial dysfunction has shown a pre-
dominant role.8 Moreover, the majority of the studies
investigated endothelial dysfunction in patients with
chronic cerebrovascular disease or in stroke-free sub-
jects, and there are scarce data about the validity of the
relationship in patients with acute stroke. Furthermore,
growing evidence has shown that global evaluation of
SVD may provide a useful overview of its impact on
the brain,9–11 but no study so far investigated whether
endothelial dysfunction is associated with SVD burden.
Analysing data from a population of acute ischae-
mic stroke patients treated with rt-PA, we aimed to
evaluate the relationship between presence and severity
of: (i) single features of SVD and (ii) global SVD
burden and blood levels of markers of endothelial dys-
function at two different time points.
Methods
Patients
We retrospectively analysed the Italian registry of
bioloGical MArkers in acute IschaemiC stroke
(MAGIC). Briefly, MAGIC study was a multicentre
prospective observational study across 14 centres in
Italy. Patients with acute ischaemic stroke treated
with i.v. rt-PA before 4.5 h from onset were enrolled,
without age limit. Stroke severity was evaluated before
rt-PA treatment using the National Institutes of Health
Stroke Scale (NIHSS). Study protocol was approved in
every participating centre from local ethic committee.
Each patient received informed consent.
Procedures
Blood samples were obtained before rt-PA treatment
and 90 days after the index stroke. For the purposes of
the present study, we analysed the following markers of
endothelial dysfunction: von Willebrand factor (vWF),
intercellular adhesion molecule-1 (ICAM-1), vascular
cell adhesion molecule-1 (VCAM-1) and vascular endo-
thelial growth factor A (VEGF). Blood separation
from plasma was done within 240 min from sampling
and stocked at 20C; blood samples were analysed in
a central laboratory within 30 days.
Each patient received a CT scan at baseline and after
24 h (22–36 h).
SVD assessment
CT scans from each participating centre were collected
at a central core lab and three stroke neurologists (FA,
BP, VP) blinded to clinical data independently rated
leukoaraiosis, lacunes and cerebral atrophy following
STandards for ReportIng Vascular changes on
nEuroimaging criteria.12 Evaluation of SVD features
was blinded to demographic and clinical characteris-
tics. We performed a preliminary intraclass correlation
coefficient (ICC) calculation among three readers on 40
CT scans. We included in the present study all patients
with available baseline or 24 h CT scan for rating of
SVD features. Where early ischaemic changes or infarct
were too large to allow rating of SVD, evaluation of
SVD features was made only in the non-ischaemic
hemisphere. We separately graded leukoaraiosis sever-
ity in anterior (score: 0–2) and posterior (score: 0–2)
with Van Swieten Scale (VSS), obtaining a five-point
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scale for severity evaluation.13 We defined lacunes as
round or ovoidal hypodense lesions 20 mm of diam-
eter in basal ganglia, white matter and brainstem.
We evaluated cortical and central cerebral atrophy
with a three-point scale (0¼ ‘none’, 1¼ ‘moderate’
and 2¼ ‘severe’) against a reference template and
summed the single scores to obtain a five-point scale
for evaluation of global cerebral atrophy.14 To evaluate
global SVD, we assigned 1 point for each of the fol-
lowing if present: lucencies (VSS  1) in anterior or
posterior periventricular white matter, lacunes 1
and presence (1) of cerebral atrophy. The combined
four-point ordinal score evaluated the global burden of
SVD ranging from 0 (no imaging features of SVD) to 3
(presence of each SVD feature scored as severe for each
imaging variable). The concept of SVD score has been
previously tested with regards to cerebral hypoperfu-
sion, clinical outcomes and blood–brain barrier perme-
ability.10,11,15 As previously reported,16 we also
combined leukoaraiosis and lacunes into a combined
score. Absence of leukoaraiosis and lacunes was
marked as 0, presence of one of these as 1 and presence
of both as 2.
Statistical analysis
We performed a natural logarithmic transformation
of crude values of levels of endothelial dysfunction
markers to obtain normally distributed data. We
described demographic and clinical characteristics of
the population with summary statistics, and used
Pearson v2, Kruskal–Wallis or analysis of variance
(ANOVA) test, as appropriate, to test differences
among groups. To investigate unadjusted associations,
we used the ANOVA of the distribution of baseline and
90-day levels of markers of endothelial dysfunction and
(1) single features of SVD and (2) the SVD score.
We retained associations with p values <0.1 from the
unadjusted analysis and built a multivariable linear
regression model adjusting for age, sex, stroke severity,
hypertension, diabetes, smoke. We considered statisti-
cally significant a p-value <0.05. We carried out statis-
tical analysis with SPSS for Windows (version 22.0;
SPSS, Armonk NY, IBM Corp.).
Results
Baseline characteristics of population
From the whole population of the MAGIC study
(n¼ 327), 263 (80%) had CT scan available for SVD
assessment. Main reasons for excluded patients were
poor quality of images and missed centralisation of
the CT scans. Evaluation of cerebral atrophy was not
possible in seven patients, and lacune rating was not
possible in one patient; this left 255 patients for the
analysis of global SVD score (i.e. leukoaraiosis,
lacunes, brain atrophy ratings). At 90 days, 21 (8%)
patients died, and 44 (18%) of the remaining patients
did not have the follow-up blood sample. This left 190
(75%) patients for the 90-day analysis. Regarding SVD
signs with CT scans, ICC ranged from good to excel-
lent among three readers (ICC for leukoaraiosis¼ 0.87;
lacunes¼ 0.76; cerebral atrophy¼ 0.89).
Main characteristics of population are shown in
Table 1. Mean age (SD) was 69 (13) years, 154
(59%) were male. Median NIHSS was 12 (IQR¼ 7–
17). Among vascular risk factors, hypertension was the
most frequent (62%). Median onset to treatment time
was 165 (IQR¼ 140–180) min. A total of 94 (36%)
patients had some degree of leukoaraiosis; 86 (33%)
had one or more lacunes; 205 (78%) patients had cere-
bral atrophy. As expected, patients with leukoaraiosis
had higher rates of hypertension (75% versus 55%;
p< 0.05) and smoke exposure (43% versus 27%;
p< 0.05). Patients with cerebral atrophy more frequent-
ly presented hypertension (68% versus 37%; p< 0.05)
and atrial fibrillation (26% versus 10%, p< 0.05). No
differences were observed between patients with or with-
out lacunes.
SVD features and baseline levels of biomarkers
of endothelial dysfunction
At baseline, levels of vWF were higher in patients with
leukoaraiosis (mean 5.1 versus 4.9; p¼ 0.007) and in
patients with cerebral atrophy (5.0 versus 4.9;
p¼ 0.027), whereas there was no difference in patients
with lacunes. ICAM-1, VCAM-1 and VEGF levels
showed no significant differences in patients with or
without SVD signs (see Supplemental table 1).
After adjustment for age, sex, hypertension, diabetes
and smoke, neither leukoaraiosis (p¼ 0.222) nor cere-
bral atrophy (p¼ 0.881) was associated with vWF levels.
SVD and 90-day levels of biomarkers of endothelial
dysfunction
Ninety-day analysis demonstrated a difference among
levels of all markers in patients with SVD signs com-
pared to those without, as shown in Table 2. ICAM-1
levels were increased in patients with leukoaraiosis
(mean 12.4 versus 12.1; p¼ 0.002) and in patients
with lacunes (mean 12.3 versus 12.1; p¼ 0.078),
VCAM-1 levels were higher in patients with leukoar-
aiosis (mean 13.3 versus 12.9; p¼ 0.002), VEGF was
increased in patients with lacunes (mean 4.6 versus 4.0;
p¼ 0.005) and vWF was higher in patients with leu-
koaraiosis (mean 5.0 versus 4.8; p¼ 0.012) and with
cerebral atrophy (mean 4.9 versus 4.7; p¼ 0.034).
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Adjusted linear regression analysis showed an inde-
pendent association between presence of leukoaraiosis
and ICAM-1 (b¼ 0.21; p¼ 0.016), and VCAM-1
(b¼ 0.19; p¼ 0.025) levels, whereas the association
with vWF levels was not confirmed (b¼ 0.12;
p¼ 0.142). Lacunes were associated to VEGF levels
(b¼ 0.21; p¼ 0.009), but not with ICAM-1 levels
(b¼ 0.09; p¼ 0.304).
Cerebral atrophy was not independently associated
with 90-day vWF levels (b¼0.01; p¼ 0.914).
Global SVD burden and biomarkers of endothelial
dysfunction
At baseline, only vWF levels were associated with
increasing SVD burden; however, in linear regression
analysis, the association was not confirmed (b¼ 0.09;
p¼ 0.274). At 90 days, all markers of endothelial dys-
function were associated with combined features of
SVD (Table 2). After adjustment, the SVD score con-
firmed a non-statistically significant association with
ICAM-1 and VCAM-1 (b¼ 0.18, p¼ 0.066; b¼ 0.18,
p¼ 0.065, respectively), whereas there was an indepen-
dent association between the SVD score and VEGF
(b¼ 0.26; p¼ 0.006) (Figure 1).
Considering the score with combined leukoaraiosis
and lacunes, and without cerebral atrophy
(Supplemental Table 2), only baseline vWF levels
showed an increase with the increasing of the score
(mean 4.9 versus 5.0 versus 5.1; p¼ 0.029). At 90
days, univariate analysis showed that levels of
ICAM-1 (mean 12.0 versus 12.3 versus 12.4;
p¼ 0.002), VCAM-1 (mean 12.9 versus 13.2 versus
13.3; p¼ 0.009) and VEGF (mean 4.0 versus 4.3
versus 4.6; p¼ 0.033) showed a similar increase with
higher combined leukoaraiosis and lacunes score.
Adjusted linear regression analysis demonstrated that
combined leukoaraiosis and lacunes were associated
only with 90-day levels of ICAM-1 (b¼ 0.20;
p¼ 0.024), VCAM-1 (b¼ 0.20; p¼ 0.024) and VEGF
(b¼ 0.22; p¼ 0.009).
Discussion
From a population of acute ischaemic stroke patients
treated with rt-PA, we analysed the relationship between
CT signs of SVD and biomarkers of endothelial dys-
function at two different time points, representing the
acute stroke phase and the steady state. We found that
leukoaraiosis, lacunes but not cerebral atrophy were
associated with markers of endothelial dysfunction at
90 days. A global SVD score was also associated with
endothelial dysfunction at 90 days.
We did not find any association between SVD and
endothelial dysfunction during the acute stroke phase.
Few studies evaluated biomarkers levels in SVD during
the acute stroke phase, and there is a large heterogeneity
across studies.8 For example, the time between stroke
onset and blood sampling was remarkably different
among studies, suggesting a performance bias that
may translate in lack of consistency of results.
Nonetheless, previous studies demonstrated that blood
levels of endothelial and inflammatory biomarkers
increase during the acute stroke phase and then return
to baseline, suggesting a possible interference of acute
phase itself on temporal profile of biomarkers levels.17,18
Our results are in keeping with this hypothesis, showing
a lack of association between SVD and endothelial dys-
function during the acute stroke phase.
Instead, at 90 days we found that leukoaraiosis was
associated with both ICAM-1 and VCAM-1. ICAM-1
and VCAM-1 are involved in endothelial activation
during inflammatory phase, driving the extravasation
of inflammatory cells.19 Past studies demonstrated an
increase of ICAM-1 and VCAM-1 in hypertensive
patients, one of the main risk factors of SVD.20,21
Similarly, in a case–control study, Rouhl et al.22 dem-
onstrated that ICAM-1 and VCAM-1 levels were
Table 2. Biomarker levels at baseline and after 90 days across SVD score.
SVD Score 0
N¼ 39
SVD Score 1
N¼ 98
SVD Score 2
N¼ 72
SVD Score 3
N¼ 46 p
ICAM-1 baseline, meanSD 12.3 0.6 12.2 0.7 12.3 0.7 12.4 0.6 0.688
VCAM-1 baseline, meanSD 12.9 0.6 12.9 0.7 12.8 0.7 12.8 1.6 0.930
VEGF baseline, meanSD 4.7 1.1 4.4 1.1 4.6 1.0 4.8 0.9 0.220
vWF baseline, meanSD 4.9 0.4 4.9 0.5 5.1 0.5 5.1 0.4 0.016
ICAM-1 90 days, meanSD 12.2 0.6 11.9 1.0 12.4 0.5 12.4 0.5 0.004
VCAM-1 90 days, meanSD 13.1 0.5 12.8 1.1 13.3 0.6 13.3 0.5 0.005
VEGF 90 days, meanSD 4.0 1.4 4.0 1.4 4.2 1.1 4.7 1.0 0.055
vWF 90 days, meanSD 4.6 0.7 4.8 0.6 5.0 0.6 5.0 0.7 0.041
ICAM-1 intercellular adhesion molecule-1; SD: standard deviation; SVD: small vessel disease; VCAM-1: vascular cell adhesion molecule-1; VEGF:
vascular endothelial growth factor; vWF: von Willebrand factor.
Bold values¼ p<0.05
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associated with SVD features. Moreover, in 296 elderly
stroke-free subjects, Markus et al.6 demonstrated an
association between levels of ICAM-1 and increasing
white matter lesions volumes after three and six years,
suggesting a possible causal role of ICAM-1 for white
matter lesions and their progression. Our results sup-
port the findings of the aforementioned studies and
extend the association in patients with previous
stroke and concurrent SVD, thus strengthening the
relationship between ICAM-1, VCAM-1 and SVD.
We found that pre-existing lacunar infarcts, as a
marker of SVD, were associated with increasing levels
of VEGF. VEGF is the most specific growth factor for
endothelium and is commonly involved in angiogenesis.
An analysis from the Framingham study on 1863 healthy
subjects demonstrated that VEGF levels were associated
with increased risk of ischaemic stroke.23 Similarly to our
findings, VEGF levels were also higher in patients with
silent brain infarcts and concurrent lacunar stroke, sup-
porting the association between VEGF and lacunar
SVD.24 Furthermore, we found that the combined SVD
score showed a meaningful association with VEGF, sup-
porting a key role of VEGF in SVD process. Moreover,
the SVD score of leukoaraiosis and lacunes showed asso-
ciations with ICAM-1, VCAM-1 and VEGF. Such
results confirm that assessment of total SVD burden
could be useful in the evaluation of the impact of this
condition on the brain. In a past study, Hassan et al.5
assessed total SVD burden in 110 patients with lacunar
stroke and leukoaraiosis and showed an increase of endo-
thelial activity expressed by ICAM-1 levels related to
SVD severity compared to 60 controls. We also found a
dose-effect response related to SVD severity and endo-
thelial activity which reinforces our results and suggests a
biological gradient of the relationship. Previous attempts
of validation of a global SVD score have been per-
formed;10,11,25,26 however, we acknowledge that a SVD
score needs derivation and refinement in different settings
(e.g. clinical, pathophysiological) with appropriate
sample size and study design.
Figure 1. Associations between SVD score and markers of endothelial dysfunction at 90 days. Data are means (95%
confidence interval).
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We were not able to demonstrate an association
between cerebral atrophy and endothelial dysfunction.
Cerebral atrophy has been included among imaging
markers of SVD,12 but is also a common finding in
neurodegeneration. However, SVD findings are fre-
quently observed in patients with primary neurodegen-
eration, alluding to an overlap between
neurodegeneration and SVD.27–29 Furthermore, as pre-
viously suggested by other authors,9,30 the lack of asso-
ciation with brain atrophy may imply that endothelial
dysfunction is a specific process linked to SVD rather
than to primary neurodegenerative causes.
Our study has limitations. First, we used CT instead
of MR (i.e. imaging gold standard) for evaluation of
SVD signs. Unavoidably we lost information about
SVD using CT (e.g. enlarged perivascular spaces, micro-
bleeds); however, core features of SVD such as lacunes
and leukoaraiosis can be detected also with CT.
Furthermore, we assessed SVD only at a single time
point (i.e. during the acute stroke phase), whereas
blood samples were taken at two time points.
Progression of SVD might have influenced levels of cir-
culating markers of endothelial dysfunction, but a rele-
vant evolution of SVD in only three months is unlikely.
Finally, as a retrospective and cross-sectional study, we
cannot draw conclusions about causal relationship
between SVD and endothelial dysfunction, rather we
report associations in keeping with previous studies,
and we suggest that evaluation of SVD and endothelial
dysfunction could be more reliable during the steady
state and not during the acute phase of stroke.
The strengths of our study are the centralised,
blinded and independent rating of SVD features CT
scan among three different readers, the centralised
analysis of blood samples, the assessment of SVD
with qualitative and reproducible standardised scales
following experts’ consensus.
In conclusion, in patients with ischaemic stroke we
demonstrated a relation between SVD and endothelial
dysfunction at 90 days after stroke. Specifically, we
observed that leukoaraiosis and lacunes were associated
with markers of endothelial dysfunction, and that global
SVD burden was consistently associated with VEGF.
Our results confirm previous findings, supporting that
endothelial dysfunction, particularly VEGF, may be
involved in pathologic process of SVD. Acute phase of
stroke could confound associations between endothelial
dysfunction and SVD; therefore future studies should
focus on the steady state rather than on the acute phase.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of
this article.
Funding
The author(s) disclosed receipt of the following financial sup-
port for the research, authorship, and/or publication of this
article: The main study, Biological Markers Associated with
Acute Ischemic Stroke (MAGIC) Study was funded by grants
from Italian Ministry of Health, 2006 Finalized Research
Programmes (RFPS-2006-1-336520). This study was partially
funded by Ente Cassa di Risparmio di Firenze (2010.06.03).
The funding body had no role in the study design.
Acknowledgements
We thank the hospital staff for data collection: M. Acampa,
Siena; M. Bacigaluppi, Milano; A. Chiti, Pisa; A. De Boni,
Vicenza; M.L. De Lodovici, Varese; F. Galati, Vibo Valentia;
N. Marcello, Reggio Emilia; N. Micheletti, Verona; F.
Muscia, Como; E. Paolino, Ferrara; P. Palumbo, Prato;
P. Tosi, Rozzano; E. Mossello, Firenze; M.R. Tola,
Ferrara, M. Torri, Firenze. We thank Dr Paolo Mattiolo
for the help in figure preparation.
Ethical approval
Study protocol was approved in every participating centre
from local ethical committee.
Informed consent
Each patient enrolled in the study received informed consent.
Guarantor
FA is the corresponding author and the guarantor of the
present work.
Contributorship
FA, AG, BP, SB, VP, DI, conceived the study, analysed and
revised the data, draft the manuscript. BG and AMG ana-
lysed laboratory sample and reviewed the draft. GP per-
formed the statistical analysis. PN, MN, GB, PB, EF, DC,
AN, FM, GO, FP, RT, MS, DT and RA reviewed and
approved the manuscript.
Data access
Coordinating centre (Florence) had full access to the study
data. All authors had access to study data upon request to the
Coordinating centre. Data are online on a dedicated website
(http://www.stroketeam.it/magic/).
References
1. Pantoni L. Cerebral small vessel disease: from pathogen-
esis and clinical characteristics to therapeutic challenges.
Lancet Neurol 2010; 9: 689–701.
2. Norrving B. Lacunar infarcts: no black holes in the brain
are benign. Pract Neurol 2008; 8: 222–228.
3. Wardlaw JM, Smith C and Dichgans M. Mechanisms of
sporadic cerebral small vessel disease: insights from neu-
roimaging. Lancet Neurol 2013; 12: 483–497.
Arba et al. 125
4. Stevenson SF, Doubal FN, Shuler K, et al. A systematic
review of dynamic cerebral and peripheral endothelial
function in lacunar stroke versus controls. Stroke 2010;
41: 434–442.
5. Hassan A, Hunt BJ, O’Sullivan M, et al. Markers of
endothelial dysfunction in lacunar infarction and ischae-
mic leukoaraiosis. Brain 2003; 126: 424–432.
6. Markus HS, Hunt B, Palmer K, et al. Markers of endo-
thelial and hemostatic activation and progression of cere-
bral white matter hyperintensities: longitudinal results of
the Austrian Stroke Prevention Study. Stroke 2005;
36: 1410–1414.
7. Wiseman S, Marlborough F, Doubal F, et al. Blood
markers of coagulation, fibrinolysis, endothelial dysfunc-
tion and inflammation in lacunar stroke versus non-
lacunar stroke and non-stroke: systematic review and
meta-analysis. Cerebrovasc Dis 2014; 37: 64–75.
8. Poggesi Pasi M, Pescini F, Pantoni L, et al. Circulating
biologic markers of endothelial dysfunction in cerebral
small vessel disease: a review. J Cereb Blood Flow
Metab 2016; 36: 72–94.
9. Staals J, Makin SD, Doubal FN, et al. Stroke subtype,
vascular risk factors, and total MRI brain small-vessel
disease burden. Neurology 2014; 83: 1228–1234.
10. Arba F, Inzitari D, Ali M, et al. Small vessel disease and
clinical outcomes after IV rt-PA treatment. Acta Neurol
Scand 2017; 136: 72–77.
11. Arba F, Mair G, Carpenter T, et al. Cerebral white
matter hypoperfusion increases with small-vessel disease
burden. Data from the third International Stroke Trial.
J Stroke Cerebrovasc Dis 2017; 26: 1506–1513.
12. Wardlaw JM, Smith EE, Biessels GJ, et al. STandards for
ReportIng Vascular changes on nEuroimaging (STRIVE
v1). Neuroimaging standards for research into small
vessel disease and its contribution to ageing and neuro-
degeneration. Lancet Neurol 2013; 12: 822–838.
13. Van Swieten JC, Hijdra A, Koudstaal PJ, et al. Grading
white matter lesions on CT and MRI: a simple scale.
J Neurol Neurosurg Psychiatry 1990; 53: 1080–1083.
14. Collaborative Group IST-3. Association between brain
imaging signs, early and late outcomes, and response to
intravenous alteplase after acute ischaemic stroke in the
third International Stroke Trial (IST-3): secondary anal-
ysis of a randomised controlled trial. Lancet Neurol 2015;
14: 485–496.
15. Arba F, Leigh R, Inzitari D, et al. Blood-brain barrier
leakage increases with small vessel disease in acute ische-
mic stroke. Neurology 2017; 89: 2143–2150.
16. Arba F, Palumbo V, Boulanger JM, et al. Leukoaraiosis
and lacunes are associated with poor clinical outcomes in
ischemic stroke patients treated with intravenous throm-
bolysis. Int J Stroke 2016; 11: 62–67.
17. Horstmann S, Kalb P, Koziol J, et al. Profiles of matrix
metalloproteinases, their inhibitors, and laminin in stroke
patients: influence of different therapies. Stroke 2003;
34: 2165–2170.
18. Matsuo R, Ago T, Kamouchi M, et al. Clinical signifi-
cance of plasma VEGF value in ischemic stroke –
research for biomarkers in ischemic stroke (REBIOS)
study. BMC Neurol 2013; 13: 32.
19. Yang L, Froio RM, Sciuto TE, et al. ICAM-1 regulates
neutrophil adhesion and transcellular migration of
TNF-alpha-activated vascular endothelium under flow.
Blood 2005; 106: 584–592.
20. Bhat SA, Goel R, Shukla R, et al. Platelet CD40L
induces activation of astrocytes and microglia in hyper-
tension. Brain Behav Immun 2016; 59: 173–189.
21. Iadecola C and Davisson RL. Hypertension and cerebro-
vascular dysfunction. Cell Metab 2008; 7: 476–484.
22. Rouhl RP, Damoiseaux JG, Lodder J, et al. Vascular
inflammation in cerebral small vessel disease. Neurobiol
Aging 2012; 33: 1800–1806.
23. Pikula A, Beiser AS, Chen TC, et al. Serum brain-derived
neurotrophic factor and vascular endothelial growth
factor levels are associated with risk of stroke and vascu-
lar brain injury: Framingham study. Stroke 2013;
44: 2768–2775.
24. Kwon HS, Kim YS, Park HH, et al. Increased VEGF
and decreased SDF-1a in patients with silent brain infarc-
tion are associated with better prognosis after first-ever
acute lacunar stroke. J Stroke Cerebrovasc Dis 2015;
24: 704–710.
25. Klarenbeek P, van Oostenbrugge RJ, Rouhl RP, et al.
Ambulatory blood pressure in patients with lacunar
stroke: association with total MRI burden of cerebral
small vessel disease. Stroke 2013; 44: 2995–2999.
26. Staals J, Booth T, Morris Z, et al. Total MRI load of
cerebral small vessel disease and cognitive ability in older
people. Neurobiol Aging 2015; 36: 2806–2811.
27. METACOHORTS Consortium. METACOHORTS for
the study of vascular disease and its contribution to cog-
nitive decline and neurodegeneration: an initiative of the
Joint Programme for Neurodegenerative Disease
Research. Alzheimers Dement 2016; 12: 1249–1235.
28. Kebets V, Gregoire SM, Charidimou A, et al. Prevalence
and cognitive impact of medial temporal atrophy in a
hospital stroke service: retrospective cohort study. Int J
Stroke 2015; 10: 861–867.
29. Arba F, Quinn T, Hankey GJ, et al. Cerebral small vessel
disease, medial temporal lobe atrophy and cognitive
status in patients with ischaemic stroke and transient
ischaemic attack. Eur J Neurol 2017; 24: 276–282.
30. Wiseman SJ, Bastin ME, Jardine CL, et al. Cerebral
small vessel disease burden is increased in systemic
lupus erythematosus. Stroke 2016; 47: 2722–2728.
126 European Stroke Journal 4(2)
